The combination of AZD1152 showed anti-cancer drugs or ionizing radiation enhanced antitumor effects compared with AZD1152 alone.62, 66,75,76 Although the pr Clinical data are promising, EPO906 Epothilone B a signal that AZD1152 appeared induced mitotic aberrations but not always sufficient apoptosis in AML lead models.70, 77 However, convincing pr and clinical data led to phase I trials, despite the large number of pr clinical trials with AZD1152 is conceived study in humans is still forming.

Phase I studyadministered AZD1152 in a 2-hour infusion w Weekly in a dose-escalation design for 13 patients with advanced pretreated solid malignancies.78 DLT was grade 3 neutropenia observed at dose of 450mg, with a few other side effects. In these patients, bone marrow recovery occurred about 14 days after administration of the dose that is Similar to Herk Mmliche cytostatics.
Three patients with various solid tumors has been reported, three stable disease, the best response was evaluated. Aloe-emodin A phase I / II of the maximum tolerated Adjusted dose of AZD1152 study evaluated as a continuous infusion administered 7 days every 21 days for patients with advanced AML.79 This study included 32 patients with de novo or secondary Rer AML from MDS Preferences Shore or exposure to certain chemotherapy dose-finding. The maximum tolerated dose was 1200 mg, as determined by the DLT mucositis and stomatitis. H Ufigsten adverse events were febrile neutropenia and nausea. Of the 32 patients there were 16 Todesf Lle, but 14 were from the progression of LAM assessed, and 7 with a clinical response.
The clinical response was incomplete to a complete remission at a dose of 1200mg, two complete remissions with Ndigen blood count recovery in 400mg and 800mg cohorts, and four partial remissions. 32 more patients were included in the efficacy study, in which all patients U 1200 mg by continuous infusion 7 days every 21 days. Population of patients were in Part B Like in Part A of febrile neutropenia and stomatitis than the h Ufigsten side effects in 12 patients was identified. In Part B, there were five deaths, three due to disease progression and 2 due to infectious Sen complications. Eight patients had a clinical response, with 2 CR, 3 CR and 3 PR. No studies were evaluated correlate the AML cells after exposure to AZD1152 HQPA the polyploid With the Lebensf Ability of the cells and should be addressed in future research.
There are currently several phase I and phase II clinical trials in progress evaluating AZD1152 in several solid and h Dermatological malignacies.28 Although the clinical relevance of this Ph Months owing is unknown, was resistance to AZD1152 in cell cultures of colon cancer and induces these cancers. 80 pancreatic cell cultures were intentionally cause with sublethal doses of AZD1152 with the intention of resistance and the Aufkl tion of the cause incubated. This study found that both cell lines, of ABC transporters, MDR1, and BCRP, both cellular Ren efflux pump for many drugs are highly regulated, resulting in a resistance 100 times the wild-type cells, AZD1152. In addition, discovered the upregulation of MDR1 and BCRP by AZD1152 product cross-resistance to the pan-Aurora kinase inhibitor VX 680/MK 0457.80 3.1.3 give GSK1070916 GSK1070916, thanks to a cross, testing and refinement of structure activity relationship, binds competitively to